The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.
 
Inger Johanne Zwicky Eide
No Relationships to Disclose
 
Aslaug Helland
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Simon Ekman
Research Funding - Boehringer Ingelheim
 
Saulius Cicenas
No Relationships to Disclose
 
Jussi Koivunen
Stock and Other Ownership Interests - Bristol-Myers Squibb; MSD; Orion
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Faron Pharmaceuticals; MSD; Pfizer; Roche; Takeda
Research Funding - Roche
Expert Testimony - AstraZeneca; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Bjørn Henning Grønberg
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Roche
 
Odd Terje Brustugun
Honoraria - AstraZeneca; Boehringer Ingelheim; MSD Oncology; Novartis
Consulting or Advisory Role - MSD Oncology (Inst)
Research Funding - Abbvie (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)